Interpace Biosciences Total Liabilities

Interpace Biosciences (IDXG) currently reports a total liabilities of $11M as of June 2026. That compares with $14M in the prior-year period — down 16.6% year over year. Use the charts on this page to explore Interpace Biosciences's total liabilities history and peer comparisons.

Interpace Biosciences's total liabilities decreased from $14M to $11M — a 16.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Interpace Biosciences reported $11M in total liabilities as of June 2026. That compares with $14M in the prior-year period — down 16.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Interpace Biosciences, and consider following IDXG for alerts when major investors trade the stock.